You missed this bit ."...Takeda were growing below market.."In other words they have captured a niche but not at the expense of CSL. Lots of medical treatments out there that may be very good but only the uber rich can afford them.
The CSL pattern, page-271
-
- There are more pages in this discussion • 1,046 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add CSL (ASX) to my watchlist
|
|||||
Last
$308.87 |
Change
0.310(0.10%) |
Mkt cap ! $149.0B |
Open | High | Low | Value | Volume |
$307.48 | $309.17 | $306.25 | $37.24M | 120.9K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
3 | 43 | $308.83 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$308.85 | 50 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
5 | 44 | 308.790 |
6 | 84 | 308.780 |
5 | 54 | 308.770 |
2 | 20 | 308.760 |
1 | 7 | 308.750 |
Price($) | Vol. | No. |
---|---|---|
308.890 | 34 | 3 |
308.900 | 38 | 1 |
308.910 | 12 | 1 |
308.940 | 9 | 1 |
308.950 | 32 | 4 |
Last trade - 11.34am 16/07/2024 (20 minute delay) ? |
Featured News
CSL (ASX) Chart |
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham / Dr Alan Dunton, MD & CEO / Non-Executive Director
James Graham / Dr Alan Dunton
MD & CEO / Non-Executive Director
SPONSORED BY The Market Online